{"id":3344,"date":"2023-04-06T21:28:13","date_gmt":"2023-04-06T21:28:13","guid":{"rendered":"https:\/\/founderlodge.com\/latest-news\/?p=3344"},"modified":"2023-04-06T21:28:15","modified_gmt":"2023-04-06T21:28:15","slug":"avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions","status":"publish","type":"post","link":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/","title":{"rendered":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-44.png\" alt=\"\" class=\"wp-image-3345\" width=\"172\" height=\"172\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-44.png 200w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-44-150x150.png 150w\" sizes=\"(max-width: 172px) 100vw, 172px\" \/><\/figure>\n\n\n\n<p><a href=\"https:\/\/www.avspulse.com\/\">AVS<\/a> announced $8.8 million Series B financing round. The early-stage medical device company&#8217;s primary goal is to treat severely calcified arterial disease. The Series B financing round was led by <a href=\"https:\/\/www.biostar.capital\/\">BioStar Capital<\/a> and<a href=\"https:\/\/www.cuegrowthpartners.com\/\"> CUE Growth Partners<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"563\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45-1024x563.png\" alt=\"\" class=\"wp-image-3346\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45-1024x563.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45-300x165.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45-768x422.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45-1536x845.png 1536w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-45.png 1549w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>AVS is an early-stage medical device company focused on treating severely calcified arterial disease in a safe and effective manner. Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and <a href=\"https:\/\/www.linkedin.com\/in\/robert-chisena-72aa2339\/\">Robert Chisena<\/a>, Ph.D., Chief Technical Officer at AVS founded it in 2018.<\/p>\n\n\n\n<p>The new funding, according to AVS, will accelerate clinical trial timelines for the company&#8217;s Pulse device, a pulsatile intravascular lithotripsy (IVL) system for peripheral applications, as well as advance development and preclinical work on a pulsatile IVL device for coronary cases. The Pulse system is a balloon-based platform that uses pressure waves in frequent bursts to break up calcium and expand calcified arteries.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"564\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-46-1024x564.png\" alt=\"\" class=\"wp-image-3347\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-46-1024x564.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-46-300x165.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-46-768x423.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-46.png 1515w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>&#8220;Our preliminary trial results demonstrated that we can successfully treat patients with multiple lesions with a single device,&#8221; Dr. Jon George, MD, an interventional cardiologist at the University of Pennsylvania Health System in Philadelphia, Pennsylvania, said in an AVS press release. &#8220;In our initial study, we saw patients report a reduction in leg pain, an increase in blood flow to the leg, and an improvement in their ability to walk.&#8221; This patient population requires easier access to advanced therapies, which this platform has the potential to provide.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AVS announced $8.8 million Series B financing round. The early-stage medical device company&#8217;s primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners. AVS is an early-stage medical device company focused on treating severely calcified arterial disease in a safe and effective [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":3348,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.2.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.<\/title>\n<meta name=\"description\" content=\"AVS announced $8.8 million Series B financing round. The early-stage medical device company&#039;s primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company&#039;s primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.\" \/>\n<meta property=\"og:description\" content=\"AVS announced $8.8 million Series B financing round. The early-stage medical device company&#039;s primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company&#039;s primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\" \/>\n<meta property=\"og:site_name\" content=\"Founder Lodge Latest News\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T21:28:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-06T21:28:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-47.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1532\" \/>\n\t<meta property=\"og:image:height\" content=\"844\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ucheezuma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ucheezuma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\"},\"author\":{\"name\":\"ucheezuma\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\"},\"headline\":\"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.\",\"datePublished\":\"2023-04-06T21:28:13+00:00\",\"dateModified\":\"2023-04-06T21:28:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\"},\"wordCount\":249,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"articleSection\":[\"Daily Startup Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\",\"name\":\"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\"},\"datePublished\":\"2023-04-06T21:28:13+00:00\",\"dateModified\":\"2023-04-06T21:28:15+00:00\",\"description\":\"AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.\",\"breadcrumb\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/founderlodge.com\/latest-news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"name\":\"Founder Lodge Latest News\",\"description\":\"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.\",\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\",\"name\":\"Founder Lodge\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Founder Lodge\"},\"image\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\",\"name\":\"ucheezuma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"caption\":\"ucheezuma\"},\"url\":\"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.","description":"AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/","og_locale":"en_US","og_type":"article","og_title":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.","og_description":"AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.","og_url":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/","og_site_name":"Founder Lodge Latest News","article_published_time":"2023-04-06T21:28:13+00:00","article_modified_time":"2023-04-06T21:28:15+00:00","og_image":[{"width":1532,"height":844,"url":"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/image-47.png","type":"image\/png"}],"author":"ucheezuma","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ucheezuma","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#article","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/"},"author":{"name":"ucheezuma","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3"},"headline":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.","datePublished":"2023-04-06T21:28:13+00:00","dateModified":"2023-04-06T21:28:15+00:00","mainEntityOfPage":{"@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/"},"wordCount":249,"commentCount":0,"publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"articleSection":["Daily Startup Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/","url":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/","name":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions. - Founder Lodge Latest News AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions.","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/#website"},"datePublished":"2023-04-06T21:28:13+00:00","dateModified":"2023-04-06T21:28:15+00:00","description":"AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial AVS announced $8.8 million Series B financing round. The early-stage medical device company's primary goal is to treat severely calcified arterial disease. The Series B financing round was led by BioStar Capital and CUE Growth Partners.","breadcrumb":{"@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/founderlodge.com\/latest-news\/avs-raises-8-8m-in-series-b-funding-to-accelerate-clinical-trials-for-pulsatile-intravascular-lithotripsy-solutions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/founderlodge.com\/latest-news\/"},{"@type":"ListItem","position":2,"name":"AVS Raises $8.8M in Series B Funding to Accelerate Clinical Trials for Pulsatile Intravascular Lithotripsy Solutions."}]},{"@type":"WebSite","@id":"https:\/\/founderlodge.com\/latest-news\/#website","url":"https:\/\/founderlodge.com\/latest-news\/","name":"Founder Lodge Latest News","description":"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.","publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/founderlodge.com\/latest-news\/#organization","name":"Founder Lodge","url":"https:\/\/founderlodge.com\/latest-news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Founder Lodge"},"image":{"@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3","name":"ucheezuma","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","caption":"ucheezuma"},"url":"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/"}]}},"_links":{"self":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/3344"}],"collection":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/comments?post=3344"}],"version-history":[{"count":1,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/3344\/revisions"}],"predecessor-version":[{"id":3349,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/3344\/revisions\/3349"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media\/3348"}],"wp:attachment":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media?parent=3344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/categories?post=3344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/tags?post=3344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}